A cancer treatment based on synergy between anti-angiogenic and immune cell therapies

Journal of Theoretical Biology

Volumn 394, Issue , 2016, Pages 197-211

  Soto Ortiz, Luis ^a  

^a East Los Angeles College   (United States)

Author keywords

Immunosuppression; Immunotherapy; Mathematical modeling; Monoclonal antibody; Tumor angiogenesis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; TUMOR ANTIGEN; VASCULOTROPIN A;

ANTIBODY; CANCER; CELL ORGANELLE; DISEASE TREATMENT; IMMUNE SYSTEM; MATHEMATICAL ANALYSIS; NUMERICAL MODEL; TUMOR;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL THERAPY; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; IMMUNE CELL THERAPY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MATHEMATICAL MODEL; MODEL; PRIORITY JOURNAL; SIMULATION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL COUNT; CELL PROLIFERATION; COMPUTER SIMULATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE EVASION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; CELL COUNT; CELL PROLIFERATION; COMPUTER SIMULATION; DENDRITIC CELLS; HUMANS; IMMUNE EVASION; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84957075682     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2016.01.026     Document Type: Article

References (77)

1. Azinovic I., Calvo F., Puebla F., et al. Long-term normal tissue effects of intraoperative electron radiation therapy (Ioert): late sequelae, tumor recurrence, and second malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:597-604.
2. Azim H., de Azambuja E., Colozza M., Bines J., Piccart M.J. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann. Oncol. 2011, 22:1939-1947. 10.1093/annonc/mdq683.
3. Arciero J., Jackson T., Kirschner D. A mathematical model of tumor-immune evasion and siRNA treatment. Discret. Contin. Dyn. Syst.-Ser. B 2004, 4:39-58.
4. Akdis C.A., Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001, 103:131-136. 10.1046/j.1365-2567.2001.01235.x.
5. Bokemeyer C., Schmoll H. Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol. 1995, 13:283-292.
6. Bender B.C., Schindler E., Friberg L.E. Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br. J. Clin. Pharmacol. 2013, 1-42. 10.1111/bcp.12258.
7. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102-3108.
8. Baginska J., Viry E., Paggetti J., Medves S., Berchem G., et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 2013, 4:1-13. 10.3389/fimmu.2013.00490.
9. Cameron M.A., Davis A.L. A Mathematical Model of Angiogenesis in Glioblastoma Multiforme 2009, Arizona State University.
10. Chimal-Ramírez G.K., Espinoza-Sánchez N.a, Fuentes-Pananá E.M. Protumor activities of the immune response: Insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J. Oncol. 2013, 2013:1-16. 10.1155/2013/835956.
11. Connolly E.C., Freimuth J., Akhurst R.J. Complexities of TGF-Beta targeted cancer therapy. Int. J. Biol. Sci. 2012, 8:964-978. 10.7150/ijbs.4564.
12. Della Porta M., Danova M., Rigolin G.M., Brugnatelli S., Rovati B., et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005, 68:276-284. 10.1159/000086784.
13. Enderling H., Chaplain M.A.J. Mathematical modeling of tumor growth and treatment. Curr. Pharm. Des. 2014, 20:1-7.
14. Eftimie R., Bramson J.L., Earn D.J.D. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull. Math. Biol. 2011, 73:2-32. 10.1007/s11538-010-9526-3.
15. Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J. Sci. 2014, 2014:1-25. 10.1155/2014/734515.
16. Elliott R.L., Blobe G.C. Role of transforming growth factor beta in human cancer. J. Clin Oncol. 2005, 23:2078-2093. 10.1200/JCO.2005.02.047.
17. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335. 10.1016/j.bbrc.2005.05.132.
18. Finley S.D., Dhar M., Popel A.S. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front. Oncol. 2013, 3:196. 10.3389/fonc.2013.00196.
19. Gabrilovich D., Chen H., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
20. Gorelik L., Flavell R. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2002, 2:46-53. 10.1038/nri704.
21. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202:919-929. 10.1084/jem.20050463.
22. Gavilondo J.V., Hernández-Bernal F., Ayala-Ávila M., de la Torre a V., de la Torre J., et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 2014, 32:2241-2250. 10.1016/j.vaccine.2013.11.102.
23. Ganapathy V., Ge R., Grazioli A., Xie W., Banach-Petrosky W., et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 2010, 9:122. 10.1186/1476-4598-9-122.
24. Ghiringhelli F., Ménard C., Terme M., Flament C., Taieb J., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202:1075-1085. 10.1084/jem.20051511.
25. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20-37. 10.1634/theoncologist.12-1-20.
26. Hodgson D.C., Gilbert E.S., Dores G.M., Schonfeld S.J., Lynch C.F., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J. Clin. Oncol. 2007, 25:1489-1497. 10.1200/JCO.2006.09.0936.
27. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., et al. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 2004, 56:549-580. 10.1124/pr.56.4.3.549.
28. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013.
29. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomark. Prev. 2010, 19:1893-1907. 10.1158/1055-9965.EPI-10-0437.
30. Jellema A.P., Slotman B.J., Doornaert P., Leemans C.R., Langendijk J.a Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:751-760. 10.1016/j.ijrobp.2007.04.021.
31. Joshi B., Wang X., Banerjee S., Tian H., Matzavinos A., et al. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. J. Theor. Biol. 2009, 259:820-827. 10.1016/j.jtbi.2009.05.001.
32. Kaur S., Chang T., Singh S.P., Lim L., Mannan P., et al. CD47 signaling regulates the immunosuppressive activity of VEGF in T Cells. J. Immunol. 2014, 193:3914-3924. 10.4049/jimmunol.1303116.
33. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007, 121:1-14. 10.1111/j.1365-2567.2007.02587.x.
34. Kusmartsev S., Gabrilovich D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 2006, 25:323-331.
35. Lipshultz S.E., Adams M.J., Colan S.D., Constine L.S., Herman E.H., et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1955. 10.1161/CIR.0b013e3182a88099.
36. Louzoun Y., Xue C., Lesinski G.B., Friedman A. A mathematical model for pancreatic cancer growth and treatments. J. Theor. Biol. 2014, 351:74-82. 10.1016/j.jtbi.2014.02.028.
37. Liao K.-L., Bai X.-F., Friedman A. Mathematical modeling of interleukin-35 promoting tumor growth and angiogenesis. PLoS One 2014, 9:e110126. 10.1371/journal.pone.0110126.
38. Liu C., Zhang L., Chang X., Cheng Y., Cheng H., et al. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin. J. Cancer Res. 2012, 24:130-137. 10.1007/s11670-012-0130-y.
39. Li Y., Wang M.-N., Li H., King K.D., Bassi R., et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 2002, 195:1575-1584. 10.1084/jem.20020072.
40. Lutz A.M., Willmann J.K., Cochran F.V., Ray P., Gambhir S.S. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med. 2008, 5:1287-1297. 10.1371/journal.pmed.0050170.
41. Mathers, C.D., Boschi-pinto, C., Lopez, A.D., 2001. Cancer incidence, mortality and survival by site for 14 regions of the world. World Health Organisation, vol. 13, pp. 1-47.
42. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631. 10.1038/nrc2444.
43. Morera Y., Bequet-Romero M., Ayala M., Pérez P.P., Castro J., et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012, 30:368-377. 10.1016/j.vaccine.2011.10.082.
44. Michaelson J., Satija S., Moore R., Weber G., Halpern E., et al. Estimates of the sizes at which breast cancers become detectable on mammographic and clinical grounds. J. Women Imaging 2003, 5:3-10. 10.1097/00130747-200302000-00002.
45. Michaelson J.S., Halpern E., Kopans D.B. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 1999, 212:551-560.
46. Maher J., Davies E.T. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br. J. Cancer 2004, 91:817-821. 10.1038/sj.bjc.6602022.
47. Osada T., Chong G., et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57:1115-1124. 10.1016/j.jsbmb.2011.07.002.Identification.
48. Ohm J.E., Gabrilovich D.I., Sempowski G.D., Kisseleva E., Parman K.S., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886. 10.1182/blood-2002-07-1956.
49. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa-B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160:1224-1232.
50. Oelkrug C., Ramage J.M. Enhancement of T cell recruitment and infiltration into tumours. Clin. Exp. Immunol. 2014, 178:1-8. 10.1111/cei.12382.
51. Okaji Y., Tsuno N.H., Saito S., Yoneyama S., Tanaka M., et al. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur. J. Surg Oncol. 2006, 32:363-370. 10.1016/j.ejso.2006.01.016.
52. Park H.J. Chemotherapy induced peripheral neuropathic pain. Korean J. Anesth. 2014, 67:4-7. 10.4097/kjae.2014.67.1.4.
53. Palumbo M.O., Kavan P., Miller W.H., Panasci L., Assouline S., et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front. Pharmacol. 2013, 10.3389/fphar.2013.00057.
54. Poleszczuk J., Hahnfeldt P., Enderling H. Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS One 2015, 10.1371:e0120007. 10.1371/journal.pone.0120007.
55. Pinzon-Charry A., Maxwell T., López J.A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 2005, 83:451-461. 10.1111/j.1440-1711.2005.01371.x.
56. Prager G., Poettler M., Unseld M., Zielinski C. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl. Lung Cancer Res. 2011, 1:14-25. 10.3978/j.issn.2218-6751.2011.11.02.
57. Ribba B., Holford N.H., Magni P., Trocóniz I., Gueorguieva I., et al. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacomet. Syst. Pharmacol. 2014, 3:e113. 10.1038/psp.2014.12.
58. Robertson-Tessi M., El-Kareh A., Goriely A. A mathematical model of tumor-immune interactions. J. Theor. Biol. 2012, 294:56-73. 10.1016/j.jtbi.2011.10.027.
59. Schwartz C.L. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 1999, 4:45-54.
60. Schaapveld M., Visser O., Louwman M.J., De Vries E.G.E., Willemse P.H.B., et al. Risk of new primary nonbreast cancers after breast cancer treatment: a dutch population-based study. J. Clin. Oncol. 2008, 26:1239-1246. 10.1200/JCO.2007.11.9081.
61. Mathematical Methods and Models in Biomedicine 2013, 426. Springer. A. Stevens, M.C. Mackey (Eds.).
62. Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 2006, 28:1779-1802. 10.1016/j.clinthera.2006.11.015.
63. Shi Y., Yu P., Zeng D., Qian F., Lei X., et al. Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity. FEBS J. 2014, 281:3882-3893. 10.1111/febs.12923.
64. Saito H., Tsujitani S., Ikeguchi M., Maeta M., Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 1998, 78:1573-1577.
65. Selvaraj S., Raundhal M., Patidar A., Saha B. Anti-VEGF antibody enhances the antitumor effect of CD40. Int. J. Cancer 2014, 135:1983-1988. 10.1002/ijc.28833.
66. Sánchez-reyes K., Bravo-cuellar A., Hernández-flores G., Lerma-díaz J.M., Jave-suárez L.F., et al. Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-Like suppressor phenotype with change in toll-like receptor profile. Biomed. Res. Int. 2014, 2014:1-11. 10.1155/2014/683068.
67. Shimabukuro-vornhagen A., Draube A., Liebig T.M., Rothe A., Kochanek M., et al. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 2012, 31:47.
68. Verheul H.M.W., Pinedo H.M. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGFReceptor kinase inhibitors. Clin. Breast Cancer 2000, 1:S80-S84. 10.3816/CBC.2000.s.015.
69. Voron T., Marcheteau E., Pernot S., Colussi O., Tartour E., et al. Control of the immune response by pro-angiogenic factors. Front. Oncol. 2014, 4:70. 10.3389/fonc.2014.00070.
70. Voron T., Colussi O., Marcheteau E., Pernot S., Zinzindohoué F., et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015, 212:139-148. 10.1084/jem.20140559.
71. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.a, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13:1253-1259. 10.1158/1078-0432.CCR-06-2309.
72. Wilson S., Levy D. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull. Math Biol. 2012, 74:1485-1500. 10.1007/s11538-012-9722-4.
73. Wu H.C., Huang C.T.C.D. Anti-angiogenic therapeutic drugs for treatment of human cancer. Cancer Mol. 2008, 4:37-45.
74. Widakowich C., de Castro G., de Azambuja E., Dinh P., Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12:1443-1455. 10.1634/theoncologist.12-12-1443.
75. Wang B., Kaumaya P.T.P., Cohn D.E. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol. Oncol. 2010, 119:564-570. 10.1016/j.ygyno.2010.07.037.
76. Wada J., Suzuki H., Fuchino R., Yamasaki A., Nagai S., et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009, 29:881-888.
77. Ziogas A., Gavalas N.G., Tsiatas M., Tsitsilonis O., Politi E., et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 2012, 107:1869-1875. 10.1038/bjc.2012.468.